-
1.发明公开NTRK1 GENETIC MARKERS ASSOCIATED WITH PROGRESSION OF ALZHEIMER’S DISEASE 审中-公开与阿尔茨海默氏症相关的遗传标记NTRK1的进展
公开(公告)号：EP1709058A2
公开(公告)日：2006-10-11
申请号：EP04811574.5
申请日：2004-11-22
发明人： AERSSENS, Jeroen , ATHANASIOU, Maria , BRAIN, Carlos , COHEN, Nadine , DAIN, Bradley , DENTON, R., Rex , JUDSON, Richard, S. , OZDEMIR, Vural , REED, Carol, R.
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172
摘要： Haplotypes in the NTRK1 gene associated with progression of Alzheimer’s Disease are disclosed. Compositions and methods for detecting these NTRK1 haplotypes are disclosed.
-
2.发明公开
公开(公告)号：EP1646729A2
公开(公告)日：2006-04-19
申请号：EP04778129.9
申请日：2004-07-12
发明人： AERSSENS, Jeroen , ATHANASIOU, Maria , BRAIN, Carlos , COHEN, Nadine , DAIN, Bradley , DENTON, R., Rex , JUDSON, Richard, S. , OZDEMIR, Vural , REED, Carol, R.
IPC分类号： C12Q1/68 , C07D491/10 , A61K31/554
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： Haplotypes in the CHRNA2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CHRNA2 hyplotypes in a variety of clinical applications are disclosed. Such applications include articles of a manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CHRNA2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer’s patients based upon their haplotype profile.
-
公开(公告)号：EP1233365A3
公开(公告)日：2004-11-17
申请号：EP02007044.7
申请日：2000-06-26
IPC分类号： G06F19/00
摘要： Method(s), computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlations between an individual's haplotypes or genotypes and a clinical outcome; methods, program and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.
-
4.发明公开METHOD AND SYSTEM FOR DETERMINING HAPLOTYPES FROM A COLLECTION OF POLYMORPHISMS 审中-公开方法和系统用于确定从单倍型多态性的集合
公开(公告)号：EP1290613A1
公开(公告)日：2003-03-12
申请号：EP01927246.7
申请日：2001-04-18
IPC分类号： G06F19/00
摘要： Methods, computer programs and databases for determining haplotypes from a collection of polymorphisms are provided. These include methods, programs, and databases to find and measure the frequency of haplotypes in the general population; and methods, programs, and databases for predicting an individual's haplotypes from the individual's genotype for a gene.
-
公开(公告)号：EP1233365A2
公开(公告)日：2002-08-21
申请号：EP02007044.7
申请日：2000-06-26
IPC分类号： G06F19/00
摘要： Method(s), computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlations between an individual's haplotypes or genotypes and a clinical outcome; methods, program and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.
摘要翻译： 方法，计算机程序和数据库来分析和利用基因单体型信息。 这些包括方法，程序和数据库，以查找和测量一般人群中单体型的频率; 方法，程序和数据库，以查明个体的单体型或基因型与临床结果之间的相关性; 方法，程序和数据库，以预测个体基因型个体的单倍型为基因; 以及基于个体的基因型或单体型来预测个体对治疗的临床反应的方法，程序和数据库。
-
6.发明公开DRUG TARGET ISOGENES: POLYMORPHISMS IN THE 5-HYDROXYTRYPTAMINE RECEPTOR 1A GENE 审中-公开药物目的等基因：多态性5-羟色胺1A受体基因
公开(公告)号：EP1208112A1
公开(公告)日：2002-05-29
申请号：EP00962018.8
申请日：2000-08-01
CPC分类号： C07K14/70571 , A61K38/00
摘要： Polynucleotides comprising one or more of 3 novel single nucleotide polymorphisms in the human 5-hydroxytryptamine receptor 1A gene (HTR1A) gene are described. Compositions and methods for detecting one or more of these polymorphisms are also disclosed. In addition, various genotypes and haplotypes for HTR1A gene that exist in the population are described.
-
7.发明公开HAPLOTYPE MARKERS AND METHODS OF USING THE SAME TO DETERMINE RESPONSE TO TREATMENT 审中-公开单倍型标记，并确定一个BEHANDLHUNG响应的使用
公开(公告)号：EP1747291A2
公开(公告)日：2007-01-31
申请号：EP05779971.0
申请日：2005-05-04
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C07K14/70528 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to methods for diagnosing or predicting responsiveness to treatment, such as Alefacept, by determining the presence of a nucleotide at one or more polymorphic sites within a haplotype marker. The present invention identifies multiple haplotypes that are associated with response to Alefacept. The haplotype markers identified by the present invention and methods of the invention can be particularly useful for diagnosing or predicting susceptibility to skin diseases, such as Psoriasis.
-
8.发明公开APOE GENETIC MARKERS ASSOCIATED WITH AGE OF ONSET OF ALZHEIMER'S DISEASE 审中-公开与年龄相关Alzheimer病APOE基因标志首次亮相
公开(公告)号：EP1743036A2
公开(公告)日：2007-01-17
申请号：EP05705750.7
申请日：2005-01-14
发明人： AERSSENS, Jeroen , ATHANASIOU, Maria , BRAIN, Carlos , COHEN, Nadine , DAIN, Bradley , DENTON, R. Rex , JUDSON, Richard S. , OZDEMIR, Vural , REED, Carol R.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172
摘要： Haplotypes in the APOE gene associated with age of onset of Alzheimer’s Disease are disclosed. Compositions and methods for detecting and using these APOE haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these APOE haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.
-
9.发明公开NTRK1 GENETIC MARKERS ASSOCIATED WITH AGE OF ONSET OF ALZHEIMER'S DISEASE 审中-公开与年龄阿尔茨海默病相关的遗传标记NTRK1爆发
公开(公告)号：EP1678328A2
公开(公告)日：2006-07-12
申请号：EP04794919.3
申请日：2004-10-14
发明人： AERSSENS, Jeroen , ATHANASIOU, Maria , BRAIN, Carlos , COHEN, Nadine , DAIN, Bradley , DENTON, R., Rex , JUDSON, Richard, S. , OZDEMIR, Vural , REED, Carol, R.
CPC分类号： G01N33/6896 , C12Q1/6883 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172
摘要： Haplotypes in the NTRK1 gene associated with age of onset of Alzheimer’s Disease are disclosed. Compositions and methods for detecting and using these NTRK1 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these NTRK1 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.
-
公开(公告)号：EP1425415A2
公开(公告)日：2004-06-09
申请号：EP02757301.3
申请日：2002-08-20
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention provides methods and materials to identify genetic abnormalities that predispose an individual to ion-channel diseases. The invention provides four polymorphic sites in the KCNQ1 gene that cause reduced conductance of the associated potassium ion channel current and a variant form of the KCNE1 gene which causes decreased conductance though the channel. The variant form of KCNE1 also acts synergistically with variants of KCNQ1 to cause further decreased conductance than either variant alone. The invention further provides polymorphisms in ion channel genes showing a higher frequency in populations afflicted with ion channel diseases or within control groups. The detection of these polymorphic sites that produce the potassium ion channel protein variants in either heterozygous or homozygous form in a subject indicates that the subject has, or is susceptible to, ion channel diseases such as congenital or acquired cardiac arrhythmia, LQT syndrome, SIDS, epilepsy, or hearing loss.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.013 秒)
